

Supplementary Table 14. The number of all-cause and cardiovascular death in valsartan new users in 2018

Death	PSM	From January 1, 2018 to July 6, 2018			From July 7, 2018 to December 31, 2018		
		Original	Eventually NDMA-uncontaminated	NDMA-contaminated	Original	Eventually NDMA-uncontaminated	NDMA-contaminated
All-cause	Event	12,800	2,132	3,907	12,388	2,207	3,690
	IR (95% CI) ^{a)}	15.77 (15.49–16.04)	11.29 (10.81–11.77)	17.94 (17.38–18.51)	16.03 (15.75–16.31)	12.27 (11.76–12.79)	17.80 (17.23–18.38)
Cardiovascular	Event	3,358	517	966	3,147	497	924
	IR (95% CI) ^{a)}	4.14 (4.00–4.28)	2.74 (2.51–2.98)	4.44 (4.16–4.72)	4.07 (3.93–4.22)	2.76 (2.53–3.02)	4.46 (4.17–4.75)

PSM, propensity score matching; NDMA, N-nitrosodimethylamine; IR, incidence rate; CI, confidence interval.

^{a)}Incidence rate per 1,000 person-years is calculated for each valsartan group and clinical outcome.